Testing zavegepant nasal spray in children with migraines
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether the medicine zavegepant (given as a nasal spray) is safe and works well for children aged 6 to 11 who have a history of migraines. If your child gets migraines, this study may help find a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 11 years old.
- Your child must have had migraines (with or without aura) for at least 6 months.
- Your child must weigh more than 15 kg (about 33 pounds).
- Your child cannot have a constant, unending headache that never goes away.
- Your child cannot have certain other medical conditions that might affect the study, like liver problems or abnormal heart tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.
This study tests if the medicine rimegepant is safe for people with migraine. You may be able to join if you have had migraine for at least a year, have 4–14 migraine days per month, and have not had good results with other migraine medicines called triptans.
This trial studies whether rimegepant can reduce how often migraine attacks happen in children and teens. It also looks at safety and how well the treatment fits day-to-day life and school activities.
This trial tests two new migraine medicines, rimegepant and zavegepant, given to people in the emergency department to see how well they work for stopping a migraine headache quickly.
This study tests an experimental nasal spray (zavegepant) for quickly stopping episodic cluster headache attacks. It's for people who have been diagnosed with episodic cluster headache and whose attacks usually last 45 minutes or more without treatment.
This study tests how well a new acute migraine medicine, zavegepant, works and is tolerated in people who are already taking a CGRP-targeting preventive medication. It may help you find an effective treatment when you get a migraine attack.
Hear when a new Acute Treatment of Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.